A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KYTX SEC filings page.
This page shows Kyverna Therapeutics, Inc. (KYTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Kyverna's reported economics are dominated by development spending, with operating cash use funded largely through external financing.
The near match between the 2025 net loss of$161.3M and operating cash flow of-$153.7M indicates that reported losses are translating into cash use rather than being mostly non-cash. Free cash flow was-$153.7M while capital expenditures were only$5K , so the cash requirement comes primarily from ongoing operations and development activity.
Research and development reached
A current ratio of 7.8x and debt-to-equity of 0.1x describe a balance sheet with substantial short-term coverage and limited debt relative to equity. Financing cash flow moved from
Financial Health Signals
We do not publish a peer-relative financial health score for Kyverna Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Kyverna Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Kyverna Therapeutics, Inc. reported a net loss of $161.3M while operations used $153.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Kyverna Therapeutics, Inc. reported an operating loss of $169.8M against $489K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Kyverna Therapeutics, Inc.'s EBITDA was -$42.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Kyverna Therapeutics, Inc. reported a net loss of $41.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Kyverna Therapeutics, Inc. earned -$0.68 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Kyverna Therapeutics, Inc. recorded an outflow of $35.5M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Kyverna Therapeutics, Inc. held $31.8M in cash against $25.0M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Kyverna Therapeutics, Inc.'s quarterly ROE was -31.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 7.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.3 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Kyverna Therapeutics, Inc. invested $27.0M in research and development in Q3 2026. This represents a decrease of 11.3% from the same quarter a year earlier. Against the prior quarter it is up 9.0%.
Kyverna Therapeutics, Inc. invested $174K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 8600.0% from the same quarter a year earlier.
Not reported for Q3 2026.
KYTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $27.0M-11.3% | $24.8M-30.8% | $30.1M-19.7% | $30.0M-10.4% | $30.5M+4.3% | $35.8M+31.1% | $37.4M+66.5% | $33.5M+95.1% |
| SG&A Expenses | $15.9M+92.0% | $14.8M+71.8% | $11.3M+13.2% | $9.3M+22.6% | $8.3M-13.6% | $8.6M+40.6% | $10.0M+44.9% | $7.6M+79.4% |
| Operating Income | -$42.9Mn/m | -$39.6Mn/m | -$41.4Mn/m | -$39.3Mn/m | -$38.7Mn/m | -$44.4Mn/m | -$47.4Mn/m | -$41.0Mn/m |
| EBITDA | -$42.6Mn/m | -$39.1Mn/m | -$41.0Mn/m | N/A | -$38.3Mn/m | -$43.9Mn/m | -$46.9Mn/m | N/A |
| Interest Expense | $728K+10300.0% | $674K+4714.3% | $667K+2568.0% | N/A | $7K-78.1% | $14K-64.1% | $25K-43.2% | N/A |
| Net Income | -$41.9Mn/m | -$38.3Mn/m | -$39.7Mn/m | -$37.8Mn/m | -$36.8Mn/m | -$42.1Mn/m | -$44.6Mn/m | -$37.5Mn/m |
| EPS (Basic) | -$0.68n/m | -$0.63n/m | -$0.66n/m | -$0.79n/m | -$0.85n/m | -$0.97n/m | -$1.03 | -$0.88 |
| EPS (Diluted) | -$0.68n/m | -$0.63n/m | -$0.66n/m | -$0.79n/m | -$0.85n/m | -$0.97n/m | -$1.03 | -$0.88 |
| Diluted Shares (Avg) | 62M+42.7% | 61M+40.9% | 60M+39.8% | N/A | 43M+0.6% | 43M+0.2% | 43M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
KYTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $189.4M+1.2% | $219.8M-3.0% | $257.0M-1.4% | $293.8M-3.6% | $187.2M-44.8% | $226.5M-37.6% | $260.7M-33.2% | $304.6M+305.1% |
| Current Assets | $176.3M+0.8% | $206.5M-3.6% | $241.7M-2.4% | $283.0M-2.6% | $174.9M-46.2% | $214.3M-38.6% | $247.7M-34.0% | $290.6M+379.0% |
| Cash & Equivalents | $31.8M-6.9% | $31.8M-40.5% | $32.2M-43.4% | $124.1M+28.4% | $34.2M-67.4% | $53.4M-59.4% | $56.9M-74.6% | $96.6M+178.9% |
| Short-Term Investments | $138.8M+1.3% | $167.6M+5.9% | $204.3M+9.9% | $155.2M-18.1% | $137.0M-36.9% | $158.2M-26.3% | $185.8M+27.7% | $189.4M+727.0% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $56.3M+59.8% | $54.3M+28.8% | $61.4M+67.7% | $61.5M+61.7% | $35.2M-3.5% | $42.1M+42.3% | $36.6M+26.4% | $38.1M-56.9% |
| Current Liabilities | $25.1M-25.8% | $22.8M-42.7% | $29.7M-10.9% | $36.5M+8.1% | $33.9M+9.3% | $39.8M+69.5% | $33.3M+52.3% | $33.8M+70.0% |
| Non-Current Liabilities | $31.1M+2226.1% | $31.5M+1243.8% | $31.8M+847.5% | $25.1M+482.6% | $1.3M-75.7% | $2.3M-61.8% | $3.4M-53.0% | $4.3M-93.7% |
| Long-Term Debt | $25.0M | $24.9M | N/A | $24.7M | N/A | N/A | N/A | N/A |
| Total Equity | $133.2M-12.4% | $165.5M-10.2% | $195.6M-12.7% | $232.3M-12.9% | $151.9M-49.8% | $184.4M-44.7% | $224.0M-37.9% | $266.6Mn/m |
| Retained Earnings | -$544.8Mn/m | -$502.9Mn/m | -$464.6Mn/m | -$424.8Mn/m | -$387.0Mn/m | -$350.2Mn/m | -$308.2Mn/m | -$263.5Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
KYTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$35.4Mn/m | -$40.3Mn/m | -$41.6Mn/m | -$33.5Mn/m | -$43.3Mn/m | -$31.9Mn/m | -$44.9Mn/m | -$37.1Mn/m |
| Depreciation & Amortization | $274K-34.0% | $434K-15.7% | $351K-29.9% | $368K-34.6% | $415K-25.6% | $515K-2.8% | $501K+3.9% | $563K+21.9% |
| Stock-Based Compensation | $3.6M+34.1% | $3.5M+39.3% | $3.2M+46.7% | N/A | $2.7M-20.9% | $2.5M+96.1% | $2.2M-5.1% | N/A |
| Capital Expenditures | $174K+8600.0% | N/A | N/A | N/A | $2K-98.0% | $4K-99.6% | $0-100.0% | $532K+59.3% |
| Free Cash Flow | -$35.5Mn/m | N/A | N/A | N/A | -$43.3Mn/m | -$32.0Mn/m | -$44.9Mn/m | -$37.6Mn/m |
| Investing Cash Flow | $28.5M+26.4% | $36.1M+23.9% | -$50.2M-1000.0% | -$17.3M-159.2% | $22.6M+3236.8% | $29.2Mn/m | $5.6Mn/m | $29.2M-7.8% |
| Financing Cash Flow | $6.9M+360.8% | $3.8Mn/m | -$101Kn/m | $140.7Mn/m | $1.5Mn/m | -$649Kn/m | -$414K-100.1% | -$215Kn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
KYTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -31.5%-7.3pp | -23.2%-0.3pp | -20.3%-0.4pp | -16.3%-2.2pp | -24.2%-12.8pp | -22.8%-14.2pp | -19.9%-12.5pp | -14.1% |
| Return on Assets | -22.1%-2.5pp | -17.4%+1.1pp | -15.5%+1.7pp | -12.9%-0.6pp | -19.7%-9.5pp | -18.6%-10.7pp | -17.1%-10.3pp | -12.3%+15.2pp |
| Current Ratio | 7.01+1.8x | 9.06+3.7x | 8.15+0.7x | 7.75-0.9x | 5.16-5.3x | 5.39-9.5x | 7.44-9.7x | 8.61+5.6x |
| Debt-to-Equity | 0.19 | 0.15 | N/A | 0.11 | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 0.42+0.2x | 0.33+0.1x | 0.31+0.2x | 0.27+0.1x | 0.23+0.1x | 0.23+0.1x | 0.16+0.1x | 0.14 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. KYTX | FY2025 | N/A | -$161.3M | N/A | $276.3M | — |
| Altimmune, Inc. ALT | FY2025 | $41K | -$88.1M | N/A | $274.4M | — |
| X4 Pharmaceuticals, Inc. XFOR | FY2025 | $35.1M | -$79.2M | N/A | $302.3M | 74/100 |
| Lyell Immunopharma, Inc. LYEL | FY2025 | $36K | -$274.4M | N/A | $333.9M | — |
| Enanta Pharmaceuticals, Inc ENTA | FY2026 | $63.0M | -$68.2M | N/A | $232.4M | 63/100 |
| Larimar Therapeutics, Inc. LRMR | FY2025 | N/A | -$165.7M | N/A | $336.9M | — |
Where Kyverna Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Kyverna Therapeutics, Inc. (KYTX) reported a net loss of $161.3M in fiscal year 2025.
Kyverna Therapeutics, Inc. (KYTX) had EBITDA of -$168.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Kyverna Therapeutics, Inc. (KYTX) had $124.1M in cash and equivalents against $24.7M in long-term debt.
Kyverna Therapeutics, Inc. (KYTX) has a return on equity of -69.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Kyverna Therapeutics, Inc. (KYTX) recorded an outflow of $153.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Kyverna Therapeutics, Inc. (KYTX) recorded an outflow of $153.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Kyverna Therapeutics, Inc. (KYTX) had $293.8M in total assets as of fiscal year 2025, including both current and long-term assets.
Kyverna Therapeutics, Inc. (KYTX) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Kyverna Therapeutics, Inc. (KYTX) invested $133.7M in research and development during fiscal year 2025.
Kyverna Therapeutics, Inc. (KYTX) had a current ratio of 7.75 as of fiscal year 2025, which is generally considered healthy.
Kyverna Therapeutics, Inc. (KYTX) had a debt-to-equity ratio of 0.11 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Kyverna Therapeutics, Inc. (KYTX) had a liabilities-to-equity ratio of 0.27 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Kyverna Therapeutics, Inc. (KYTX) had a return on assets of -54.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Kyverna Therapeutics, Inc. (KYTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $276.3M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Kyverna Therapeutics, Inc. (KYTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $276.3M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Kyverna Therapeutics, Inc. (KYTX) held $279.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $153.7M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Kyverna Therapeutics, Inc. (KYTX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Kyverna Therapeutics, Inc. (KYTX) reported a net loss of $161.3M while operations used $153.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Kyverna Therapeutics, Inc. (KYTX) reported an operating loss of $169.8M against $489K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.